1.Antithrombotic therapy and pharmaceutical care of a child with purpura nephritis complicated with lower extremity deep venous thrombosis
Weiting LIU ; Boxia LI ; Yaowen CHANG
China Pharmacy 2024;35(20):2548-2551
OBJECTIVE To provide a reference for the formulation of the antithrombotic treatment regimen of children with lower extremity deep venous thrombosis (DVT). METHODS The clinical pharmacist participated in the antithrombotic treatment of a child with purpura nephritis complicated with lower extremity DVT and formulated an individualized dosing plan for the child. Considering that the child was readmitted to the hospital when DVT of the lower extremities did not relieve after anticoagulation therapy, it was recommended that thrombolytic therapy (Enoxaparin sodium injection 30 mg, q2 h, i.d.) be initiated after joint consultation by clinical pharmacists and physicians; catheter thrombolysis and thrombolytic drug therapy were simultaneously performed (intravenous infusion of 200 000 units of Urokinase for injection, per day); great attention should be paid to the occurrence of adverse drug reactions in children, and the changes in coagulation indexes of the children should be monitored. For long-term anticoagulation therapy after discharge, clinical pharmacists recommended oral Rivaroxaban tablets 10 mg, qd, and adjusted the dose according to the weight change of the child. RESULTS The clinician adopted the pharmacist’s recommendations. After drug thrombolytic therapy, the child’s coagulation indicators returned to normal, the symptoms of lower extremity DVT improved significantly, and there were no adverse events of bleeding or other thrombotic events after discharge. CONCLUSIONS Clinical pharmacists can assist clinicians in formulating individualized treatment plans for children based on their expertise in pharmacy to ensure the rationality of medication use in children, which helps ensure the effectiveness and safety of medication for children.
2.HPLC fingerprint and three main components determination of Modified Zengye Decoction
Shiqi LIU ; Chuang WU ; Zhimin ZHU ; Feng XU ; Yaowen CHANG ; Haiyan ZHANG ; Xiaojun GOU
China Pharmacist 2024;27(6):928-936
Objective To establish a method for HPLC fingerprint analysis and determine three main components of Modified Zengye Decoction.Methods The chromatographic column was Shimadzu WondaSil C18 column(250 mm×4.6 mm,5 μm),the mobile phase was acetonitrile-0.3%aqueous phosphoric acid with a gradient elution procedure,the volume flow rate was 1.0 mL/min,the detection wavelengths were 265,203,310 and 290 nm,the column temperature was 25 ℃,and the injection volume was 20 μL.The HPLC fingerprints of the 10 batches of Modified Zengye Decoction were established,and the similarity analysis was performed by using the similarity evaluation system of chromatographic fingerprint of traditional Chinese medicine(version 2012A).The common peaks were identified and assigned,and the contents of the three main components were quantitatively determined.Results There were 17 common peaks in the fingerprints of 10 batches of Modified Zengye Decoction with similarities ranging from 0.872-0.989.The fingerprints recognized peak 9,14 and 17 as ferulic acid,aurantiamarin and harpagoside,respectively.The contents of ferulic acid,aurantiamarin and harpagoside were 0.067 3-0.174 8,0.498 8-1.522 7,0.270 9-0.802 4 mg/g,and the transfer rate were 30.74%-55.63%,11.77%-35.94%,23.15%-68.56%,respectively.Conclusion The established HPLC fingerprint analysis method combined with main components quantitative analysis method can be used for the quality analysis and control of Modified Zengye Decoction with simple analysis method and reliable results.